Clinical Pathology Division
Clinical Pathology Division
News Article | November 30, 2016
SALT LAKE CITY, UT--(Marketwired - November 30, 2016) - ARUP Laboratories, a national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, announced the appointment of Julio Delgado, MD, MS, as chief medical officer (CMO), director of laboratories, and co-chief of the Clinical Pathology Division effective January 1, 2017. Delgado's appointment fills a vacancy left by the departure of Jerry Hussong, MD, DDS. "We are fortunate to have Julio join our executive team. During his time at ARUP, Julio has been instrumental in driving ARUP's innovation and commitment to patient care. Based on his collaborative leadership style and knowledge of healthcare, we are confident that he will contribute to our success in this rapidly changing healthcare environment," said Edgar Braendle, MD, president and CEO of ARUP. Delgado joined ARUP Laboratories in 2006 as a medical director in the Department of Immunology. He served as co-executive director of the ARUP Institute for Clinical and Experimental Pathology® from 2013 to 2015. Delgado is an associate professor of pathology at the University of Utah School of Medicine. He received his MD from Universidad Industrial de Santander in Colombia and his MS degree in epidemiology from the Harvard School of Public Health, completing both his clinical residency training in clinical pathology and his research fellowship in immunology at the Harvard Medical School. He is board certified in clinical pathology and histocompatibility laboratory testing by the American Board of Pathology and the American Board of Histocompatibility and Immunogenetics. "I'm excited to take on this new opportunity and continue the important role of providing actionable, accurate, cost-efficient, and clear laboratory results that help physicians manage patient diseases and tailor treatment," said Delgado. "With my academic medical background, I'm interested in preserving and strengthening ARUP's reputation as the premiere academic reference laboratory in the country." Hussong is leaving ARUP to pursue a new opportunity in the laboratory industry. "Since joining ARUP in 2012, Jerry has worked tirelessly in promoting continuous quality improvement in our clinical operations. He has been an outstanding representative of ARUP with clients, prospective clients, professional organizations, and regulatory agencies. Jerry will be missed, and we wish him success in the next phase of his career," said Braendle. Founded in 1984, ARUP Laboratories is a leading national reference laboratory and a nonprofit enterprise of the University of Utah and its Department of Pathology. ARUP offers more than 3,000 tests and test combinations, ranging from routine screening tests to esoteric molecular and genetic assays. ARUP serves clients across the United States, including many of the nation's top university teaching hospitals and children's hospitals, as well as multihospital groups, major commercial laboratories, group purchasing organizations, military and other government facilities, and major clinics. In addition, ARUP is a worldwide leader in innovative laboratory research and development, led by the efforts of the ARUP Institute for Clinical and Experimental Pathology®.
Cavagnolli G.,Federal University of Rio Grande do Sul |
Comerlato J.,Clinical Pathology Division |
Comerlato C.,Clinical Pathology Division |
Renz P.B.,Clinical Pathology Division |
And 3 more authors.
Diabetic Medicine | Year: 2011
Aim To analyse the performance of HbA1c in diagnosing Type 2 diabetes based on fasting plasma glucose and/or 2-h plasma glucose measurements after a 75-g oral glucose tolerance test.Methods This is a study of diagnostic test accuracy in individuals referred to the Clinical Pathology Department for oral glucose tolerance testing. After fasting overnight, HbA1c, fasting plasma glucose and 2-h plasma glucose were measured. The receiver operating characteristic curve was used to evaluate the diagnostic performance of HbA1c.Results Four hundred and ninety-eight subjects (195 male, mean age 56 years) were enrolled and 115 (23.1%) were diagnosed with diabetes according to glucose-based methods and only 56 (11.2%) individuals were identified by HbA1c≥ 6.5% (48 mmol/mol) (sensitivity 20.9%, specificity 95.3%). There is poor agreement between the newly recommended criterion and the current glucose-based diagnostic criteria (κ = 0.217; P < 0.001), probably because the diagnostic methods identify different populations of patients. Adding a glucose-based method into an algorithm, as proposed by the UK Department of Health, improved HbA1c performance.Conclusions HbA1c≥ 6.5% (48 mmol/mol) showed limited sensitivity to diabetes diagnosis, although with high specificity. The results suggest that this cut-off point would not be enough to diagnose diabetes. Its use as the sole diabetes diagnostic test should be interpreted with caution to assure the correct classification of diabetic individuals. © 2010 The Authors. Diabetic Medicine © 2010 Diabetes UK.
Foroni L.,University of Bologna |
Dirani G.,Clinical Pathology Division |
Gualandi C.,University of Bologna |
Focarete M.L.,University of Bologna |
Pasquinelli G.,Clinical Pathology Division
Tissue Engineering - Part C: Methods | Year: 2010
Morphological and immunophenotypic characterization of cells grown on poly(l-lactic acid) (PLLA) electrospun scaffolds is usually performed using immunofluorescence and cryosections. However, these methods present practical limits; histological processing, on the other hand, is believed to lead to artifactual changes in the scaffold structure. Here the formalin-fixed paraffin-embedding (FFPE) procedure was tailored to process PLLA electrospun scaffolds grown with human umbilical vein endothelial cells. After 1 to 7 days of culture, the scaffolds were processed with the FFPE procedure. Using this protocol, not only cross sections but also "en face" sections were obtained. This made possible to perform the effective light microscopy analysis of cell morphology and to assess cell adhesion and penetration without considerable scaffold damage. The method was also suitable for immunohistochemical assays, such as proliferation (Ki67), extracellular matrix production (type IV collagen), survival (cleaved caspase-3), and immunophenotyping (KDR, CD44, vimentin, CD45); results were compared with those obtained using complementary techniques (scanning electron microscopy, Alamar Blue assay, and cryosections). The FFPE protocol can be safely applied to PLLA scaffolds and provides information that are essential to study the mechanisms of interaction between cells and PLLA fibers before their potential implantation in vivo. © 2010 Mary Ann Liebert, Inc.